# US 2023/0265179 A1 · Cytokine variant antibodies and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0265179 A1
- Document ID: US20230265179A1
- Status: Published application
- Kind: A1
- Application number: 18/056,648
- Filed: 2022-11-17
- Published: 2023-08-24
- Earliest claimed: 2021-11-18
- Assignees: Twist Bioscience Corporation
- Applicants: Twist Bioscience Corporation
- Inventors: Aaron SATO; Linya WANG; Fumiko AXELROD; Sean PETERSON; Tom YUAN
- Web page: https://patentgrep.com/patent/US20230265179A1

## CPC

- C07K 16/24: against cytokines, lymphokines or interferons
- C07K 16/244: {Interleukins [IL]}
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- C07K 16/2875: {against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154 (against NGF C07K16/22, against TNF C07K16/241)}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/55: Fab or Fab'
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/626: Diabody or triabody
- C07K 2317/64: comprising a combination of variable region and constant region components
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Provided herein are methods and compositions relating to cytokine variant libraries having nucleic acids encoding for immunoglobulins that bind to cytokines. Libraries described herein include variegated libraries comprising nucleic acids each encoding for a predetermined variant of at least one predetermined reference nucleic acid sequence. Further described herein are protein libraries generated when the nucleic acid libraries are translated. Further described herein are cell libraries expressing variegated nucleic acid libraries described herein.

## Claims

### Claim 1

An antibody or antibody fragment comprising a variable domain, heavy chain region (VH) and a variable domain, light chain region (VL), wherein the VH comprises an amino acid sequence at least about 90% identical to any one of SEQ ID NOs: 1-1628; and the VL comprises an amino acid sequence at least about 90% identical to any one of SEQ ID NOs: 1629-2643.

### Claim 2 (depends on 1)

The antibody or antibody fragment of claim 1, wherein the antibody is a monoclonal antibody, a polyclonal antibody, a bi-specific antibody, a multispecific antibody, a grafted antibody, a human antibody, a humanized antibody, a synthetic antibody, a chimeric antibody, a camelized antibody, a single-chain Fvs (scFv), a single chain antibody, a Fab fragment, a F(ab′)2 fragment, a Fd fragment, a Fv fragment, a single-domain antibody, an isolated complementarity determining region (CDR), a diabody, a fragment comprised of only a single monomeric variable domain, disulfide-linked Fvs (sdFv), an intrabody, an anti-idiotypic (anti-Id) antibody, or ab antigen-binding fragments thereof.

### Claim at position 3

3-5. (canceled)

### Claim 6 (depends on 1)

The antibody or antibody fragment of claim 1, wherein the VH comprises an amino acid sequence at least about 90% identical to any one of SEQ ID NOs: 1-301; and the VL comprises an amino acid sequence at least about 90% identical to any one of SEQ ID NOs: 1629-1811.

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The antibody or antibody fragment of claim 1, wherein the VH comprises an amino acid sequence at least about 90% identical to any one of SEQ ID NOs: 302-790; and the VL comprises an amino acid sequence at least about 90% identical to any one of SEQ ID NOs: 1812-2112.

### Claim 9

(canceled)

### Claim 10 (depends on 1)

The antibody or antibody fragment of claim 1, wherein the VH comprises an amino acid sequence at least about 90% identical to any one of SEQ ID NOs: 791-1187; and the VL comprises an amino acid sequence at least about 90% identical to any one of SEQ ID NOs: 2113-2357.

### Claim 11

(canceled)

### Claim 12 (depends on 1)

The antibody or antibody fragment of claim 1, wherein the VH comprises an amino acid sequence at least about 90% identical to any one of SEQ ID NOs: 1188-1628; and the VL comprises an amino acid sequence at least about 90% identical to any one of SEQ ID NOs: 2358-2643.

### Claim 13

(canceled)

### Claim 14

An antibody or antibody fragment comprising a variable domain, heavy chain region (VH), wherein the VH comprises an amino acid sequence at least about 90% identical to any one of SEQ ID NOs: 1-1628.

### Claim 15 (depends on 14)

The antibody or antibody fragment of claim 14, wherein the antibody is a monoclonal antibody, a polyclonal antibody, a bi-specific antibody, a multispecific antibody, a grafted antibody, a human antibody, a humanized antibody, a synthetic antibody, a chimeric antibody, a camelized antibody, a single-chain Fvs (scFv), a single chain antibody, a Fab fragment, a F(ab′)2 fragment, a Fd fragment, a Fv fragment, a single-domain antibody, an isolated complementarity determining region (CDR), a diabody, a fragment comprised of only a single monomeric variable domain, disulfide-linked Fvs (sdFv), an intrabody, an anti-idiotypic (anti-Id) antibody, or ab antigen-binding fragments thereof.

### Claim at position 14

16-17. (canceled)

### Claim 18 (depends on 14)

The antibody or antibody fragment of claim 14, wherein the VH comprises an amino acid sequence at least about 90% identical to any one of SEQ ID NOs: 1-301.

### Claim 19

(canceled)

### Claim 20 (depends on 14)

The antibody or antibody fragment of claim 14, wherein the VH comprises an amino acid sequence at least about 90% identical to any one of SEQ ID NOs: 302-790.

### Claim 21

(canceled)

### Claim 22 (depends on 14)

The antibody or antibody fragment of claim 14, wherein the VH comprises an amino acid sequence at least about 90% identical to any one of SEQ ID NOs: 791-1187.

### Claim 23

(canceled)

### Claim 24 (depends on 14)

The antibody or antibody fragment of claim 14, wherein the VH comprises an amino acid sequence at least about 90% identical to any one of SEQ ID NOs: 1188-1628.

### Claim 25

(canceled)

### Claim 26

An antibody or antibody fragment comprising a variable domain, light chain region (VL), wherein the VL comprises an amino acid sequence at least about 90% identical to any one of SEQ ID NOs: 1629-2643.

### Claim 27 (depends on 26)

The antibody or antibody fragment of claim 26, wherein the antibody is a monoclonal antibody, a polyclonal antibody, a bi-specific antibody, a multispecific antibody, a grafted antibody, a human antibody, a humanized antibody, a synthetic antibody, a chimeric antibody, a camelized antibody, a single-chain Fvs (scFv), a single chain antibody, a Fab fragment, a F(ab′)2 fragment, a Fd fragment, a Fv fragment, a single-domain antibody, an isolated complementarity determining region (CDR), a diabody, a fragment comprised of only a single monomeric variable domain, disulfide-linked Fvs (sdFv), an intrabody, an anti-idiotypic (anti-Id) antibody, or ab antigen-binding fragments thereof.

### Claim at position 25

28-29. (canceled)

### Claim 30 (depends on 26)

The antibody or antibody fragment of claim 26, wherein the VL comprises an amino acid sequence at least about 90% identical to any one of SEQ ID NOs: 1629-1811.

### Claim 31

(canceled)

### Claim 32 (depends on 26)

The antibody or antibody fragment of claim 26, wherein the VL comprises an amino acid sequence at least about 90% identical to any one of SEQ ID NOs: 1812-2112.

### Claim 33

(canceled)

### Claim 34 (depends on 14)

The antibody or antibody fragment of claim 14, wherein the VH comprises an amino acid sequence at least about 90% identical to any one of SEQ ID NOs: 2113-2357.

### Claim 35

(canceled)

### Claim 36 (depends on 14)

The antibody or antibody fragment of claim 14, wherein the VH comprises an amino acid sequence at least about 90% identical to any one of SEQ ID NOs: 2358-2643.

### Claim 37

(canceled)

### Claim 38

A nucleic acid composition comprising:
a) a first nucleic acid encoding a variable domain, heavy chain region (VH), wherein the VH comprises an amino acid sequence at least about 90% identical to any one of SEQ ID NOs: 1-1628;
b) a second nucleic acid encoding a variable domain, light chain region (VL), wherein the VL comprises an amino acid sequence at least about 90% identical to any one of SEQ ID NOs: 1629-2643; and
c) an excipient.

### Claim at position 35

39-48. (canceled)

### Claim 49

A nucleic acid composition comprising:
a) a first nucleic acid encoding a variable domain, heavy chain region (VH) comprising an amino acid sequence at least about 90% identical to a sequence as set forth in any one of SEQ ID NOs: 1-1628;
b) a second nucleic acid encoding a variable domain, light chain region (VL) comprising at least about 90% identical to a sequence as set forth in any one of SEQ ID NOs: 1629-2643; and
c) an excipient.

### Claim at position 37

50-58. (canceled)
